We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





COVID-19 Vaccine Could Give Immunity for At Least 12 Months, Says AstraZeneca

By HospiMedica International staff writers
Posted on 04 Aug 2020
The COVID-19 vaccine could give immunity from the coronavirus for at least 12 months or even provide two years of protection, according to the chief behind AstraZeneca’s (Cambridgeshire, England) trial.

Sir Mene Pangalos, the head of BioPharmaceuticals Research and Development told BBC Newscast that based on their studies, the scientists were hopeful that the immune response of the COVID-19 vaccine would last for at least 12 months but could stretch to 24 months or longer. More...
Their studies indicate that the most effective method of getting the correct dose in order to build up an immune response appears to be receiving two shots with a gap of weeks between each one. An ideal COVID-19 vaccine is expected to provide protection from the coronavirus for a minimum of six months, as well as reduce the onward transmission of the coronavirus to contacts.

WHO chief scientist Soumya Swaminathan had recently stated that AstraZeneca’s experimental COVID-19 vaccine developed by researchers at University of Oxford was possibly the world’s leading candidate and the most advanced in terms of development. Researchers believe that an ideal COVID-19 vaccine should prove effective after one or two vaccinations and work in target populations, including older adults and those with other health conditions. AstraZeneca had already commenced large-scale, mid-stage human trials of the vaccine and human clinical studies will begin in September, followed by a Phase 3 study in December 2020.

"You get your flu shot every year, hopefully it'll last longer than that but we don't know, but we'd want it to last at least 12 months, Pangalos told BBC Newscast. "But given how contagious this virus is and how much it spreads around the world I think anything that can protect you from the disease, from becoming sick, from going into hospital, I think will be a big step forward for the world."

Related Links:
AstraZeneca


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.